Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0201 | 0.0151 | 0.0151 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0399 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0399 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0399 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0198 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0354 | 0.7743 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0399 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0399 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0399 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0399 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0399 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0246 | 0.2407 | 0.2407 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0399 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0399 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0399 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0399 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0399 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0399 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0399 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0354 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0399 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0246 | 0.2407 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0198 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0399 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0399 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0399 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0399 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0399 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0399 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Increase in footpad thickness (functional) | = 0.42 mM | Tested for increase in foot-pad thickness (mm) by its effect on cellular immune response in mice against sheep red blood cells by the DHR method in experiment 12 at dose 3 mg/kg | ChEMBL. | 7005449 |
Increase in footpad thickness (functional) | = 0.42 mM | Tested for increase in foot-pad thickness (mm) by its effect on cellular immune response in mice against sheep red blood cells by DHR method in experiment 12 at dose 12 mg/kg | ChEMBL. | 7005449 |
Increase in footpad thickness (functional) | = 0.42 mM | Tested for increase in foot-pad thickness (mm) by its effect on cellular immune response in mice against sheep red blood cells by the DHR method in experiment 12 at dose 3 mg/kg | ChEMBL. | 7005449 |
Increase in footpad thickness (functional) | = 0.42 mM | Tested for increase in foot-pad thickness (mm) by its effect on cellular immune response in mice against sheep red blood cells by DHR method in experiment 12 at dose 12 mg/kg | ChEMBL. | 7005449 |
PFC (functional) | = 2070 | Effect on humoral immune response in mice against sheep red blood cells by the plaque-forming cell (PFC/10e6 spleen cells) method in experiment 3 at dose 12 mg/kg | ChEMBL. | 7005449 |
PFC (functional) | = 2550 | Effect on humoral immune response in mice against sheep red blood cells by the plaque-forming cell (PFC/10e6 spleen cells) method in experiment 3 at dose 3 mg/kg | ChEMBL. | 7005449 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.